Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | NQO2 | P16083 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | SRC | P12931 | 5/20 | 0.36 |
| ▸ | ABL1 | P00519 | 2/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | HCK | P08631 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.36 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.36 |
| ▸ | PRKDC | P78527 | 1/20 | 0.36 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.36 |
| ▸ | CASR | P41180 | 3/20 | 0.35 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.35 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16158053 | 0.82 | MAPT (0.36) | MAPTSRCABL1PIK3CDEGFR | |
| SCHEMBL15995719 | 0.82 | PIK3CD (0.35) | CYP19A1NQO2MAPTSRCABL1 | |
| SCHEMBL16157998 | 0.81 | BRD9 (0.40) | CYP19A1NQO2MAPTSRCABL1 | |
| SCHEMBL16154718 | 0.80 | KCNA5 (0.36) | CYP19A1NQO2SRCABL1PIK3CD | |
| SCHEMBL26033285 | 0.78 | CYP19A1 (0.40) | CYP19A1NQO2MAPTSRCABL1 | |
| SCHEMBL16006511 | 0.76 | HTT (0.35) | MAPTSRCABL1PIK3CDEGFR | |
| SCHEMBL16006423 | 0.72 | LMNA (0.40) | MAPTSRCABL1PIK3CDEGFR | |
| SCHEMBL16006818 | 0.72 | CCR4 (0.41) | CYP19A1NQO2MAPTALDH1A1MEN1 | |
| SCHEMBL15995815 | 0.71 | KCNA5 (0.51) | MAPTDCPSALDH1A1MEN1NPC1 | |
| SCHEMBL15996052 | 0.69 | PIK3CD (0.33) | SRCABL1PIK3CDEGFRHCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021262990-A1 | CAPSID INHIBITORS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2021-12-30 | — | — | WO | disclosed |
| WO-2016033243-A9 | ANTIRETROVIRAL AGENTS | GILEAD SCIENCES, INC. (US) | 2016-05-19 | — | — | WO | disclosed |
| US-20160108030-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-04-21 | — | — | US | disclosed |
| US-20160083368-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-03-24 | — | — | US | disclosed |
| US-20140303164-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2014-10-09 | — | — | US | disclosed |
| WO-2014134566-A2 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160108030-A1 | THERAPEUTIC COMPOUNDS | HAVCR2, SARS1, RPL35 | CYP19A1 677/4885NQO2 757/4885MAPT 1547/4885 |
| US-20160083368-A1 | THERAPEUTIC COMPOUNDS | HAVCR2, SARS1, G6PD | CYP19A1 854/4885NQO2 781/4885MAPT 1618/4885 |
| US-20140303164-A1 | THERAPEUTIC COMPOUNDS | HAVCR2, SARS1, G6PD | CYP19A1 854/4885NQO2 781/4885MAPT 1618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.